Sophiris Bio Inc. (SPHS) Sees Large Volume Increase
Sophiris Bio Inc. (NASDAQ:SPHS) shares saw unusually-high trading volume on Tuesday . Approximately 1,305,363 shares traded hands during mid-day trading, an increase of 4% from the previous session’s volume of 1,259,273 shares.The stock last traded at $2.65 and had previously closed at $2.47.
SPHS has been the topic of a number of recent analyst reports. Maxim Group reaffirmed a “buy” rating and issued a $4.00 target price on shares of Sophiris Bio in a research report on Thursday, March 24th. Echelon Wealth Partners reaffirmed a “buy” rating and issued a $5.00 target price on shares of Sophiris Bio in a research report on Friday, June 10th.
The stock’s market cap is $56.62 million. The stock’s 50 day moving average is $1.72 and its 200-day moving average is $1.61.
Sophiris Bio (NASDAQ:SPHS) last issued its quarterly earnings data on Monday, May 16th. The biopharmaceutical company reported ($0.13) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.19) by $0.06. On average, equities research analysts predict that Sophiris Bio Inc. will post ($0.73) earnings per share for the current year.
Sophiris Bio, Inc, formerly Protox Therapeutics Inc, is a Canada-based biopharmaceutical company focused on the research, development and commercialization of products for the treatment of urological diseases. The Company has operations based in San Diego developing a treatment for benign prostatic hyperplasia (benign prostatic hyperplasia (BPH) or enlarged prostate).
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.